Published in EMBO J on June 02, 2003
Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet (2010) 2.50
The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia (2012) 1.35
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. Genome Res (2006) 1.13
Real-time PCR mapping of DNaseI-hypersensitive sites using a novel ligation-mediated amplification technique. Nucleic Acids Res (2007) 1.03
Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal. Cell Rep (2014) 1.03
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature (2013) 0.99
Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M-CSF (CSF-1) receptor loci. Nucleic Acids Res (2003) 0.97
Mass spectrometric studies on epigenetic interaction networks in cell differentiation. J Biol Chem (2011) 0.96
A novel mode of enhancer evolution: the Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity. Genome Res (2008) 0.94
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93
RUNX1: A microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci (2013) 0.91
cis-Regulatory remodeling of the SCL locus during vertebrate evolution. Mol Cell Biol (2010) 0.90
Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex. Nucleic Acids Res (2009) 0.86
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem (2013) 0.86
Rapid, solid-phase based automated analysis of chromatin structure and transcription factor occupancy in living eukaryotic cells. Nucleic Acids Res (2005) 0.81
AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Cancer Res (2010) 0.79
Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. Exp Hematol (2010) 0.77
TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis. Mol Cell Biol (2015) 0.75
Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells. Front Genet (2013) 0.75
Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol (1980) 287.68
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Histone methylation in transcriptional control. Curr Opin Genet Dev (2002) 7.21
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell (2002) 4.37
Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development (1999) 4.21
Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity (2002) 4.15
Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep (2002) 4.13
A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood (2002) 4.06
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A (1998) 3.59
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol (1998) 3.06
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A (2001) 2.84
The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol (1995) 2.70
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol (1996) 2.42
Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J (2002) 2.40
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood (1991) 2.33
Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity (2000) 2.10
Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J (1998) 2.09
The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol (1998) 1.98
Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J (1999) 1.97
Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol (2002) 1.89
A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem (2000) 1.84
The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene (1995) 1.78
Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol (1994) 1.77
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol (1998) 1.69
Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core. Mol Cell Biol (1994) 1.60
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood (2002) 1.58
Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol (2000) 1.58
Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene (2000) 1.52
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol (2001) 1.46
AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood (2002) 1.34
Transcription factor complex formation and chromatin fine structure alterations at the murine c-fms (CSF-1 receptor) locus during maturation of myeloid precursor cells. Genes Dev (2002) 1.34
Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A (1996) 1.28
Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryot Gene Expr (1997) 1.27
Core binding factor and its role in normal hematopoietic development. Curr Opin Hematol (2001) 1.23
A highly conserved c-fms gene intronic element controls macrophage-specific and regulated expression. J Leukoc Biol (2001) 1.18
Differential transcription of exon 1 of the human c-fms gene in placental trophoblasts and monocytes. Mol Cell Biol (1989) 1.13
AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood (2000) 1.01
Identification of DNaseI hypersensitive sites within nuclei. Methods Mol Biol (2000) 1.00
Transcription factor fusions in acute leukemia: variations on a theme. Oncogene (2002) 0.93
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
The distal V(H) gene cluster of the Igh locus contains distinct regulatory elements with Pax5 transcription factor-dependent activity in pro-B cells. Immunity (2011) 2.41
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
The replacement histone H2A.Z in a hyperacetylated form is a feature of active genes in the chicken. Nucleic Acids Res (2005) 2.08
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med (2010) 1.93
PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev (2008) 1.90
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
The LPS-induced transcriptional upregulation of the chicken lysozyme locus involves CTCF eviction and noncoding RNA transcription. Mol Cell (2008) 1.81
The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity (2009) 1.67
A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the c-fms gene. Mol Cell Biol (2006) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica (2006) 1.64
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology (2014) 1.64
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood (2003) 1.60
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58
Flexible long-range loops in the VH gene region of the Igh locus facilitate the generation of a diverse antibody repertoire. Immunity (2013) 1.56
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53
The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J (2012) 1.50
Thyroid hormone-regulated enhancer blocking: cooperation of CTCF and thyroid hormone receptor. EMBO J (2003) 1.49
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45
Runx proteins regulate Foxp3 expression. J Exp Med (2009) 1.45
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res (2011) 1.44
Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood (2011) 1.41
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res (2010) 1.39
Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol (2011) 1.37
RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis. EMBO J (2012) 1.37
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood (2010) 1.36
Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage. J Biol Chem (2007) 1.36
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood (2013) 1.35
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood (2002) 1.34
Transcription factor complex formation and chromatin fine structure alterations at the murine c-fms (CSF-1 receptor) locus during maturation of myeloid precursor cells. Genes Dev (2002) 1.34
Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res (2013) 1.33
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood (2012) 1.33
Untangling the unfolded protein response. Cell Cycle (2008) 1.32
Epigenetic silencing of the c-fms locus during B-lymphopoiesis occurs in discrete steps and is reversible. EMBO J (2004) 1.28
Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene. J Biol Chem (2005) 1.26
The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol (2007) 1.23
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 1.22
Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood (2011) 1.22
The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. EMBO J (2011) 1.22
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag (2006) 1.20
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res (2008) 1.19
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem (2002) 1.18
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res (2003) 1.17
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood (2013) 1.16
Developmentally regulated recruitment of transcription factors and chromatin modification activities to chicken lysozyme cis-regulatory elements in vivo. Mol Cell Biol (2003) 1.15
Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood (2003) 1.14
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood (2007) 1.11
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol (2002) 1.09
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment. Blood (2012) 1.08
Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett (2006) 1.07
An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Res (2010) 1.07
Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev (2005) 1.06
Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells. J Biol Chem (2007) 1.06
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood (2003) 1.05
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol (2014) 1.04
The role of second autografts in the management of myeloma at first relapse. Haematologica (2006) 1.03
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer (2011) 1.02
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res (2003) 1.02
Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. Cancer Causes Control (2004) 1.01
A modified method for whole exome resequencing from minimal amounts of starting DNA. PLoS One (2012) 1.00
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica (2007) 1.00
Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther (2009) 0.99
How transcription factors program chromatin--lessons from studies of the regulation of myeloid-specific genes. Semin Immunol (2008) 0.99
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol (2003) 0.98
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica (2010) 0.98
The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction. EMBO J (2006) 0.98
Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M-CSF (CSF-1) receptor loci. Nucleic Acids Res (2003) 0.97
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer (2002) 0.97